Endocannabinoid and Opioid System Interactions in Exercise-Induced Hypoalgesia
- PMID: 28387833
- PMCID: PMC6454785
- DOI: 10.1093/pm/pnx058
Endocannabinoid and Opioid System Interactions in Exercise-Induced Hypoalgesia
Abstract
Objective: The purpose of this study was to examine the interaction between the endogenous opioid and endocannabinoid (eCB) systems in a pain modulatory process known as exercise-induced hypoalgesia (EIH).
Design: Randomized controlled trial.
Setting: Clinical research unit in a hospital.
Subjects: Fifty-eight healthy men and women (mean age = 21 ± 3 years) participated in this study.
Methods: Participants were administered (randomized, double-blind, counterbalanced procedure) an opioid antagonist (i.e., naltrexone) and a placebo prior to performing pain testing and isometric exercise.
Results: Results indicated that 2-arachidonoylglycerol (2-AG) and 2-oleoylglycerol (2-OG) increased significantly (P < 0.05) following exercise in both placebo and naltrexone conditions. In comparison, N-arachidonylethanolamine (AEA) and oleoylethanolamine (OEA) increased significantly (P < 0.05) following exercise in the placebo condition but not the naltrexone condition. There were no significant (P > 0.05) differences in palmitolethanolamine (PEA) between the placebo and naltrexone conditions.
Conclusions: As reductions in pain (i.e., EIH) were observed following both conditions, these results suggest that the opioid system may not be the primary system involved in exercise-induced hypoalgesia and that 2-AG and 2-OG could contribute to nonopioid exercise-induced hypoalgesia. Moreover, as exercise-induced increases in AEA and OEA were blocked by naltrexone pretreatment, this suggests that the opioid system may be involved in the increase of AEA and OEA following exercise.
Keywords: 2-AG; AEA; EIH Mechanisms; Isometric Exercise; Pain Modulation.
© 2017 American Academy of Pain Medicine. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com
Figures


References
-
- Hill MN, Gorzalka BB.. The endocannabinoid system and the treatment of mood and anxiety disorders. CNS Neurol Disord Drug Target 2009;86:451–8. - PubMed
-
- Tsou K, Brown S, Sañudo-Peña MC, Mackie K, Walker JM.. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 1998;832:393–411. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous